The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Results from Solitaire with the Intention for Thrombectomy (SWIFT) Study Announced at the International Stroke Conference on February 3

Wednesday, February 01, 2012

Results from Solitaire with the Intention for Thrombectomy (SWIFT) Study Announced at the International Stroke Conference on February 317:09 EST Wednesday, February 01, 2012 (Business Wire) -- Covidien:           WHO: Jeffrey Saver, MD SWIFT, Lead Author Professor of Neurology and Director UCLA Stroke Center, David Geffen School of Medicine University of California, Los Angeles   WHAT: Results from the Solitaire with the Intention for Thrombectomy (SWIFT) Study will be announced at a press conference at 8AM CT – followed by a late breaking trial presentation at 12 PM CT. The Solitaire™ FR Revascularization Device is a stent-based mechanical thrombectomy system from Covidien. It combines the ability to revascularize and retrieve the clot in a single device. The device is designed to be passed through the obstruction and deployed, thereby offering the potential for flow restoration and the ability to retrieve clots in patients experiencing acute ischemic stroke. The objective of the SWIFT study is to demonstrate substantial equivalence in the safety and effectiveness of the Solitaire™ FR Revascularization Device when compared to the MERCI® Retrieval.   WHERE: International Stroke Conference Ernest N. Morial Convention Center - Press Conference: News Media Center Room 211 - SWIFT Presentation Dr Saver: Hall D 900 Convention Center Blvd. New Orleans   WHEN: February 3, 2012   - Press Conference at 8 AM CT - SWIFT Presentation Dr Saver at 12 PM CT   ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. CovidienRachel Bloom Baglin, 508-452-6651VP, Communications, Vascular Therapiescell: 774-284-1193rachel.bloombaglin@covidien.comorDavid T. Young, 508-452-1644Manager, External Communications, Vascular Therapiescell: 774-284-2746david.young@covidien.com